Opus Genetics (IRD) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $15.00 price target on the stock.
Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 [TheStreet.com]
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
Opus Genetics (IRD) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.
Opus Genetics (IRD) had its price target raised by Wedbush from $8.00 to $10.00. They now have an "outperform" rating on the stock.